California Awards Grants for Research Projects in Nonembryonic Stem Cells
LOS ANGELES — In a tacit acknowledgment that the promise of human embryonic stem cells is still far in the future, California’s stem cell research program on Wednesday awarded grants intended to develop therapies using mainly other, less controversial cells.
The $230 million in grants awarded Wednesday to California universities and companies represent a big step toward moving stem cells from basic research toward application in treating diseases like cancer and AIDS. Grant recipients are supposed to have a therapy ready for initial human testing in four years.
But only 4 of the 14 projects involve embryonic stem cells. The others will use so-called adult stem cells or conventional drugs intended to kill cancer stem cells, which are thought to give rise to tumors.
The grants thus represent a departure from the program’s original mission. California voters approved the 10-year, $3 billion effort in 2004 largely to get around restrictions on embryonic stem cell research imposed by the administration of President George W. Bush.
Such research is ethically controversial because creation of embryonic stem cells involves the destruction of human embryos. This year, the Obama administration relaxed the previous administration’s restrictions.
Leaders of the California program say that what voters really care about are treatments for diseases, not what cell type is used. They say that from the outset the program was not restricted to the embryonic cells.
The commitment to voters was to “pursue the very best cell type for each disease,” said Robert N. Klein, the chairman of the California Institute for Regenerative Medicine, the agency that runs the program.
Still, the grant awards are likely to bolster one argument made by opponents of embryonic stem cell work: that such cells are not needed because treatments using adult cells are closer to fruition.
“This is the stuff that’s delivering for patients,” said David Prentice, senior fellow for life sciences at the Family Research Council, an organization opposed to abortion and embryonic stem cell research.
The California grants are “in a sense, not surprising,” Mr. Prentice said.
Embryonic stem cells can grow easily in culture and can turn into virtually any type of tissue in the body. The hope is that the cells might be turned into heart cells, brain cells or other types of cells to repair damaged and diseased organs.
But the embryonic stem cells themselves can grow into tumors in the body, so the cells have to be first turned into pure preparations of specific types of cells.
Adult stem cells can be obtained from the human body and turned into a more limited range of tissues. But adult stem cells have been the subject of research for a longer time and, in the form of bone marrow transplants, are already used to treat a variety of diseases.
One project financed Wednesday would involve retrieving cardiac stem cells from a patient’s heart. The cells would be multiplied in culture and then put back into the heart to try to repair damage from a heart attack.
Dr. Eduardo Marbán of Cedars-Sinai Medical Center, who will lead the project, said embryonic stem cells turn into immature heart cells that might not help an adult heart. “The last thing we want to do is grow rogue heart cells,” Dr. Marbán said.
Still, one project awarded financing would use embryonic stem cells to make insulin-producing islet cells that would implanted in the body to treat Type 1 diabetes. The $20 million for the project went to Novocell, a San Diego biotechnology company, and the University of California, San Francisco.
Other projects involving embryonic stem cells are intended to treat stroke, Lou Gehrig’s disease and the eye disease called macular degeneration.
One project will use so-called induced pluripotent stem cells, which can be made from a patient’s own skin cells and have many of the properties of embryonic stem cells. Scientists at Stanford hope to harness those cells to treat a rare but debilitating skin disease called epidermolysis bullosa.
Two projects will essentially try to replicate the reported cure last year of a patient with AIDS. The patient, in Berlin, also had leukemia and got a bone marrow transplant to treat that disease. But the bone marrow donor had a genetic makeup making him naturally resistant to H.I.V.
For a given patient with AIDS it would be nearly impossible to find a donor that is both a good match and naturally resistant to H.I.V. infection. But the two research teams plan to take a patient’s blood-forming stem cells and inactivate a gene to make them resistant to H.I.V., then put them back in the body.
In addition to the $230 million being provided by California, the governments of Canada and Britain are together contributing $43 million because some of the research will be done in those countries.
LOS ANGELES — In a tacit acknowledgment that the promise of human embryonic stem cells is still far in the future, California’s stem cell research program on Wednesday awarded grants intended to develop therapies using mainly other, less controversial cells.
The $230 million in grants awarded Wednesday to California universities and companies represent a big step toward moving stem cells from basic research toward application in treating diseases like cancer and AIDS. Grant recipients are supposed to have a therapy ready for initial human testing in four years.
But only 4 of the 14 projects involve embryonic stem cells. The others will use so-called adult stem cells or conventional drugs intended to kill cancer stem cells, which are thought to give rise to tumors.
The grants thus represent a departure from the program’s original mission. California voters approved the 10-year, $3 billion effort in 2004 largely to get around restrictions on embryonic stem cell research imposed by the administration of President George W. Bush.
Such research is ethically controversial because creation of embryonic stem cells involves the destruction of human embryos. This year, the Obama administration relaxed the previous administration’s restrictions.
Leaders of the California program say that what voters really care about are treatments for diseases, not what cell type is used. They say that from the outset the program was not restricted to the embryonic cells.
The commitment to voters was to “pursue the very best cell type for each disease,” said Robert N. Klein, the chairman of the California Institute for Regenerative Medicine, the agency that runs the program.
Still, the grant awards are likely to bolster one argument made by opponents of embryonic stem cell work: that such cells are not needed because treatments using adult cells are closer to fruition.
“This is the stuff that’s delivering for patients,” said David Prentice, senior fellow for life sciences at the Family Research Council, an organization opposed to abortion and embryonic stem cell research.
The California grants are “in a sense, not surprising,” Mr. Prentice said.
Embryonic stem cells can grow easily in culture and can turn into virtually any type of tissue in the body. The hope is that the cells might be turned into heart cells, brain cells or other types of cells to repair damaged and diseased organs.
But the embryonic stem cells themselves can grow into tumors in the body, so the cells have to be first turned into pure preparations of specific types of cells.
Adult stem cells can be obtained from the human body and turned into a more limited range of tissues. But adult stem cells have been the subject of research for a longer time and, in the form of bone marrow transplants, are already used to treat a variety of diseases.
One project financed Wednesday would involve retrieving cardiac stem cells from a patient’s heart. The cells would be multiplied in culture and then put back into the heart to try to repair damage from a heart attack.
Dr. Eduardo Marbán of Cedars-Sinai Medical Center, who will lead the project, said embryonic stem cells turn into immature heart cells that might not help an adult heart. “The last thing we want to do is grow rogue heart cells,” Dr. Marbán said.
Still, one project awarded financing would use embryonic stem cells to make insulin-producing islet cells that would implanted in the body to treat Type 1 diabetes. The $20 million for the project went to Novocell, a San Diego biotechnology company, and the University of California, San Francisco.
Other projects involving embryonic stem cells are intended to treat stroke, Lou Gehrig’s disease and the eye disease called macular degeneration.
One project will use so-called induced pluripotent stem cells, which can be made from a patient’s own skin cells and have many of the properties of embryonic stem cells. Scientists at Stanford hope to harness those cells to treat a rare but debilitating skin disease called epidermolysis bullosa.
Two projects will essentially try to replicate the reported cure last year of a patient with AIDS. The patient, in Berlin, also had leukemia and got a bone marrow transplant to treat that disease. But the bone marrow donor had a genetic makeup making him naturally resistant to H.I.V.
For a given patient with AIDS it would be nearly impossible to find a donor that is both a good match and naturally resistant to H.I.V. infection. But the two research teams plan to take a patient’s blood-forming stem cells and inactivate a gene to make them resistant to H.I.V., then put them back in the body.
In addition to the $230 million being provided by California, the governments of Canada and Britain are together contributing $43 million because some of the research will be done in those countries.
Source: New York Times
« Back to Health News
Related News
-
Sangamo Gets Stem-Cell Grant for New AIDS Therapy Oct 28, 2009 @ 06:26 PM
Oct. 28 (Bloomberg) -- Sangamo Biosciences, a developer ofgene therapies based in Richmond, California, and the City ofHope, a nonprofit treatment center in Los Angeles, were awardeda $14.6 million grant to develop a new type of AIDS treatment.
-
NIH authorizes use of first human embryonic stem cells under new policy Oct 28, 2009 @ 06:26 PM
The Obama administration on Wednesday approved the first human embryonic stem cells for experiments by federally funded scientists under a new policy designed to dramatically expand government support for one of the most promising but also most contentious fields of biomedical research.
-
San Francisco Merchants Band Together to Help Fight Breast Cancer With Susan G ... Oct 28, 2009 @ 06:26 PM
San Francisco Merchants Band Together to Help Fight Breast Cancer With SusanG. Komen's Shop For The Cure(R)The Komen Card Program Kicks off with a Night of Shopping Oct 21 and RunsThrough Oct 30SAN FRANCISCO, Oct. 21 /PRNewswire/ -- Today, the San Francisco Bay AreaAffiliate of Susan G. Komen For The Cure announced the launch of the 2009 ShopFor The Cure® program, a night of shopping and cocktails hosted by UnionSquare's finest stores.The kick-off celebration is a new addition to the Shop For The Cure® program,in its fourth year. With a $65 tax-deductible donation, shoppers receive the2009 Komen Card, which grants them a 20 percent discount card to be used atparticipating merchants from October 22 through October 30. One hundredpercent of the card donations will benefit the Komen San Francisco Bay AreaAffiliate. Cards are available at participating merchants.The following merchants are participating in the program and will becelebrating the kickoff this evening, offering refreshments and staying openlate to offer shoppers the exclusive opportunity to use their card early: -- 7 For All Mankind -- Allen Edmonds -- Bottega Veneta -- The Container Store -- Cafe Coton -- Glory Chen -- Gucci -- Hickey Freeman -- Joe's Jeans -- Kate Spade New York -- John Varvatos -- Judith Ripka Jewelry -- Paul Smith -- Stuart Weitzman -- Theory -- TSE -- Yves St. Laurent"The merchant community in San Francisco has been amazing, becoming moreinvolved with the Komen Shop For The Cure card every year," said Anne Chen,Shop For The Cure Co-Chair. "We've raised more than $150,000 to fund breastcancer research, awareness and local support with this program to date and areso pleased to introduce a festive kick-off event where shoppers, merchants,and Komen donors can start their holiday shopping in style.""This year especially, customers are eager for reasons to feel good aboutshopping," said Julie Scott, Manager of Allen Edmonds. "I can't think of abetter way to offer that than the Shop For The Cure program, which benefitssuch an important cause and provides a significant discount on luxury items."The Komen Card comes with an easy-to-use directory that contains a detailedalphabetical listing of all the stores. The discount applies only toparticipating stores and must be presented at the time of purchase. The KomenCard discount applies only to new merchandise or services purchased during theKomen Card event from October 22 through October 30, 2009. It does not applyto existing balances, prior purchases or future purchases.Additional Resources:For more information about the Komen Card program, visit:http://www.komencard.orgBecome a Facebook Fan: http://www.facebook.com/pages/Komen-Card/112559207065Follow the Komen Card on Twitter: http://twitter.com/komencardMap of the participating retailers: http://bit.ly/3Ob88zAbout Susan G. Komen For The Cure Susan G. Komen For The Cure was established in 1982 by Nancy Brinker to honorthe memory of her sister, Susan G. Komen, who died from breast cancer at theage of 36. Today, the Komen For The Cure is an international organization witha network of more than 100,000 survivors and advocates working through localAffiliates and events like the Komen Race For The Cure® to eradicate breastcancer as a life-threatening disease. A global leader in the fight againstbreast cancer, Komen fulfills its mission through the funding of innovativebreast cancer research grants, meritorious awards and educational, scientificand community outreach programs around the world. Komen , together with itsAffiliate Network, corporate partners and generous donors, has invested $1.3Billion in breast cancer research, education, screening and treatmentprograms.About the San Francisco Bay Area Affiliate of Susan G. Komen For The Cure The San Francisco Bay Area Affiliate of Susan G. Komen For The Cure -- alongwith those who generously support us with their talent, time and resources --is working to better the lives of those facing breast cancer in our community.The San Francisco Bay Area Affiliate is proud to have invested over $11million in local breast health and breast cancer awareness projects in thenine Bay Area counties of Sonoma, Napa, West Solano, Marin, San Francisco,Alameda, Contra Costa, San Mateo, and Santa Clara since our inception in 1987- 2007. We accomplish this through the Race For The Cure®, donations fromindividuals, corporate contributions, benefits by community partners, andother fund-raising efforts. Up to 75 percent of net proceeds generated by theKomen SF Bay Area Affiliate stays in the Bay Area through our annual grantsprogram to local tax exempt organizations providing breast cancer education,screening, support and treatment services to underserved women and theirfamilies. A minimum of 25 percent of our annual income is directed to thenational Susan G. Komen For The Cure Grants Program for energizing science tofind the cures.For more information about breast health or breast cancer, visit the Komen SanFrancisco's Web site, www.komensf.org, or call (415) 397-8812.SOURCE San Francisco Bay Area Affiliate of Susan G. Komen For The CureSan Francisco Bay Area Affiliate of Susan G. Komen For The Cure,+1-415-397-8812
-
Investigation: Earmarked AIDS funds lack oversight Oct 28, 2009 @ 06:26 PM
In a city whose HIV/AIDS rates are ten times the national average, one in three of D.C.'s AIDS dollars earmarked for local groups in recent years went to organizations cited for falsified documentation, few or no clients, incomplete spending records or not running any AIDS programs whatsoever. Meanwhile, District residents living with HIV/AIDS have struggled to find care.
-
Christmas Discovery on Cancer, Aging Brought Nobel to Two Women Oct 28, 2009 @ 06:26 PM
Oct. 6 (Bloomberg) -- It was Christmas Day, 1984, and CarolGreider, a 23-year-old first-year graduate student at theUniversity of California, Berkeley, couldn’t stay away from thelab where she and assistant professor Elizabeth Blackburn weretrying to untangle a genetic mystery.
